Sonoma Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sonoma Pharmaceuticals, Inc. on December 8, 2017. The filing reports the entry into a material definitive agreement to facilitate the sale of the company's common stock.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the authorization to raise up to $5 million in aggregate offering price through an "at-the-market" issuance program.
Material Changes and Agreements
- Sales Agreement: On December 8, 2017, the company entered into an At Market Issuance Sales Agreement with B. Riley FBR, Inc.
- Offering Structure: The company may issue and sell shares of common stock having an aggregate offering price of up to $5 million from time to time.
- Compensation: B. Riley FBR will receive a commission of 3.0% of the gross proceeds from any shares sold.
- Expenses: The company agreed to reimburse B. Riley FBR for certain expenses up to $25,000.
- Obligation: The company is not obligated to sell any shares, and no assurance is given regarding the price, amount, or timing of any sales.
Outlook, Risks, and Contingencies
The filing contains forward-looking statements regarding the company's intentions and future activities, including a planned spin-off. Management notes that actual results may differ materially due to risks and uncertainties. The Sales Agreement will terminate upon the earlier of the sale of all shares or as provided in the agreement terms. The filing incorporates by reference the full text of the Sales Agreement and the company's shelf registration statement on Form S-3.
Investor Verification Checklist
- Verify the current share price and trading volume to assess the potential dilution impact of a $5 million offering.
- Review the full text of the Sales Agreement (Exhibit 10.1) for specific termination clauses and sales parameters.
- Check the company's most recent Form 10-K for detailed financial health, cash runway, and the status of the planned spin-off.
- Monitor future filings to confirm if and when shares are actually sold under this agreement.